ABAnirban Bhattacharyya

Anirban Bhattacharyya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anirban Bhattacharyya has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Functional Recovery Patterns and Baseline Cardiac Power Output During Impella 5.5 Support in Heart Transplant Candidates: A Descriptive Study

    by Vrutti Patel, Saurabh Sujanyal, Anek Jena, Aayushi Pareek, Said Bateh, Jose Delgado, Aryan Pathak, Gustavo Olaizola, Ivan Huespe, Faiz Ur Rehman Saleem, et al.

    Background: The Impella 5.5 microaxial pump facilitates ambulatory mechanical circulatory support via axillary implantation, providing a model for active prehabilitation in critically ill heart transplant candidates. Whether patients with severely reduced baseline cardiac power output (CPO) can achieve meaningful ambulation during Impella 5.5 support remains uncertain. Methods: This is a retrospective descriptive study of consecutive adults with cardiogenic shock (SCAI stages C-E) who received an Impella 5.5 as a bridge to heart transplantation between April 2022 and September 2024. Cardiac Power Output was calculated via pre-implantation right heart catheterization, defined as low (≤0.60 W) or higher (>0.60 W). Measures of functional recovery include maximum walking distance per day, cumulative walking distance during Impella 5.5 support, time to first walk, and percentage of patients who walked at least once. The LOWESS method is used to illustrate overall walking distance trajectories. Results: The final analytic cohort included 80 patients: 37 (46.3%) with baseline CPO ≤0.60 W and 43 (53.8%) with baseline CPO >0.60 W. Overall, 75 of 80 patients (93.8%) ambulated at least once before transplantation, including 89.2% in the low-CPO group and 97.7% in the higher-CPO group (p = 0.176). The time to first walking day was 5 days (IQR 3-7) in the low-CPO group vs. 3 days (IQR 2-7) in the higher-CPO group (p = 0.27). Maximum daily walking distance was 5,200 ft (IQR 2,000-10,400 ft) vs. 4,000 ft (IQR 2,400-8,000 ft) (p = 0.26), while cumulative distance was 15,400 ft vs. 11,000 ft (p = 0.81). Conclusions: Prehabilitation is feasible in patients undergoing Impella 5.5 support across the spectrum of hemodynamic status. Patients with severely compromised baseline cardiac performance achieved early, substantial ambulation. Thus, Impella 5.5 appears feasible as a platform for both hemodynamic support and prehabilitation of patients awaiting heart transplantation, though larger, non-selected cohorts are needed to confirm these findings.

  • Association Between Veno-Venous Extracorporeal Membrane Oxygenation and Right Ventricular Dysfunction in Acute Respiratory Distress Syndrome Patients: A Multicenter Retrospective Propensity-Matched Study

    by Shahin Isha, Aditya A. Khanijo, Govind Pandompatam, John Kyle Bohman, Troy G. Seelhammer, Ayan Sen, John Haney, Ricardo Diaz Milian, Devang K. Sanghavi, Pablo Moreno Franco, et al.

    Emerging evidence links veno-venous extracorporeal membrane oxygenation (VV-ECMO) to right ventricular (RV) dysfunction, but the relative contribution of ECMO versus underlying disease progression remains unclear. We conducted a multicenter, retrospective, propensity-matched study including 408 intubated acute respiratory distress syndrome (ARDS) patients who were admitted between January 2020 and October 2024 in a quaternary referral hospital network within the United States and underwent at least two transthoracic echocardiograms (TTEs) after intubation. Using 1:2 propensity score matching, we adjusted for baseline comorbidities, baseline hemoglobin, lactate, and worst PaO 2 /FiO 2 ratio (P/F). Longitudinal echocardiographic changes were analyzed with a cumulative link mixed model (CLMM), evaluating RV size and function as ordinal outcomes. Within 408 patients (112 received ECMO support), propensity matching identified 55 ECMO and 110 non-ECMO patients with balanced baseline characteristics. Among 469 serial echocardiograms, RV size and function worsened more frequently in ECMO patients. In longitudinal modeling, ECMO use alone was not associated with RV dilation ( p = 0.23) or dysfunction ( p = 0.43). However, longer ECMO duration was associated with RV dilation (OR: 1.04 per day, p = 0.004) and dysfunction (odds ratio [OR]: 1.04 per day, p < 0.001). Higher ECMO circuit flow had a trend toward progressive RV dilation and dysfunction but did not reach statistical significance. These findings highlight the need for vigilant RV monitoring during ECMO support.

  • Open Access

    Comparison of SARS-CoV-2 Delta Versus Omicron Variant and Its Impact on Immunocompromised Versus Immunocompetent Population

    by Sadia Z. Shah, Parthkumar Satashia, Shahin Isha, Patrick Johnson, Katie Kunze, Abdul Moiz Khan, Jorge Sinclair, Rose Mary Attieh, Anirban Bhattacharyya, Ricardo Diaz Millian, et al.

    The Omicron variant of SARS-CoV-2 is associated with milder symptoms and lower hospitalization and mortality rates than Delta variants, although the impact of Omicron on immunocompromised patients, especially solid organ transplant (SOT) recipients, is still unclear. This study compares the hospitalization rate and outcomes between immunocompromised, immunocompetent, and SOT patients during the Delta and Omicron periods. We included adult patients who tested positive for SARS-CoV-2 on PCR or nasopharyngeal antigen test between 26 June 2021 to 8 September 2022, at our institution. A total of 12,401 COVID-19 patients were included, of which 11,055 were immunocompetent, and 1346 were immunocompromised (375 SOT recipients). Throughout the Delta and Omicron outbreaks, immunocompromised patients exhibited higher comorbidities and 30-day hospitalizations, but rates of mechanical ventilation and ICU-level care were like immunocompetent patients. During the Omicron wave, immunocompromised patients had higher unadjusted relative risk estimates (RR = 2.37, 95% CI 1.96–2.87, p < 0.05) than Delta (RR = 1.58, 95% CI 1.24–2.01, p < 0.05), with higher adjusted relative risk for hospitalization in Omicron (RR = 1.50, 95% CI 1.10–2.03, p = 0.01). Analyses show increased hospitalization risk in immunocompromised during the Omicron wave compared to the Delta wave, with no significant difference in hospitalization outcomes. The relative risk of hospitalization for SOT patients was higher in both waves.

  • Open Access

    Comparison of SARS-CoV-2 Delta Versus Omicron Variant and Its Impact on Immunocompromised Versus Immunocompetent Population

    by Sadia Z. Shah, Parthkumar Satashia, Shahin Isha, Patrick Johnson, Katie Kunze, Abdul Moiz Khan, Jorge Sinclair, Rose Mary Attieh, Anirban Bhattacharyya, Ricardo Diaz Millian, et al.

    The Omicron variant of SARS CoV-2 is associated with milder symptoms and lower hospitalization and mortality rates than Delta variants, although the impact of Omicron on immunocompromised patients, especially Solid Organ Transplant (SOT) recipients, is still unclear. This study compares the hospitalization rate and outcomes between immunocompromised, immunocompetent, and SOT patients during the Delta and Omicron periods. We included adult patients who tested positive for SARS-CoV-2 on PCR or nasopharyngeal antigen test between June 26, 2021 to September 8, 2022, at our institution. 12,401 COVID-19 patients were included, of which 11,055 were immunocompetent, and 1,346 were immuno-compromised (375 SOT recipients). Throughout the Delta and Omicron outbreaks, immunocompromised patients exhibited higher comorbidities and 30-day hospitalizations, but rates of mechanical ventilation and ICU-level care were like immunocompetent patients. During the Omicron wave, immunocompromised patients had higher unadjusted relative risk estimates (RR=2.37, 95% CI 1.96-2.87, p< 0.05) than Delta (RR=1.58, 95% CI 1.24-2.01, p< 0.05) with higher adjusted relative risk for hospitalization in Omicron (RR=1.50, 95% CI 1.10-2.03, p=0.01). Analyses show increased hospitalization risk in immunocompromised during the Omicron wave compared to the Delta wave with no significant difference in hospitalization outcomes. The relative risk of hospitalization for SOT patients was higher in both waves.

  • Open Access

    Percutaneous Temporary Mechanical Circulatory Support as a Bridge to Heart Transplantation in the Current UNOS Allocation System

    by Rohan Goswami, Jose Ruiz, Aarti Desai, Peter Wlodkowski, Basar Sareyyupoglu, Sean Kiley, Anirban Bhattacharyya, Daniel Yip, Melissa Lyle, Jose Nativi-Nicolau, et al.

    Background: Progressive heart failure cardiogenic shock (HFCS) often requires escalation to temporary or durable mechanical circulatory support (MCS) as a bridge to transplant (BTT). Following the 2018 UNOS allocation changes, our center revised its BTT strategy to optimize support and shorten wait times. At our institution, the Impella 5.5 with SmartAssist via the axillary approach was selectively used for patients who remained refractory to guideline-directed medical therapy, failed single-inotrope therapy, and were not considered suitable durable LVAD candidates by our multidisciplinary heart team. We compared transplant-related outcomes of BTT patients supported with Impella 5.5 versus durable LVAD. Methods: We performed a single-center retrospective review of all heart and heart/kidney transplant candidates at Mayo Clinic Florida from October 2018 to February 2021. INTERMACS profile, baseline characteristics, and perioperative data were collected at the time of device implantation and throughout the transplant hospitalization. Results: A total of 87 heart and 4 heart–kidney transplants were completed. Forty-five patients (49%) required MCS as BTT: 27 (60%) with a durable LVAD and 18 (40%) with an Impella 5.5. All eighteen patients with Impella 5.5 as BTT (100%) were transplanted compared to nineteen patients with durable LVAD (70%), p = 0.001. The median time from listing to transplant was substantially shorter with Impella (32 vs. 696 days, p < 0.001), and this difference persisted across INTERMACS profiles. UNOS status at transplant was more urgent for Impella than LVAD (p < 0.001). Transplant surgery following Impella support required shorter cardiopulmonary bypass time (181 vs. 219 min, p < 0.001) and resulted in lower postoperative vasoactive-inotropic requirements (7.9 vs. 13, p = 0.003). No patients in the Impella group died or were delisted while awaiting transplant, whereas 5 LVAD patients (26%) died or were removed due to LVAD complications (p < 0.001). Conclusions: Our data demonstrates that the use of the Impella 5.5 as BTT was associated with significantly shorter waitlist time, higher transplantation rates, reduced perioperative morbidity, and lower postoperative vasoactive support compared with durable LVAD as BTT. These benefits were achieved despite a higher severity of illness at transplantation in the Impella cohort.


  • Open Access

    Harnessing the Power of Technology to Transform Delirium Severity Measurement in the Intensive Care Unit: Protocol for a Prospective Cohort Study

    by Roshini Raghu, Keivan Nalaie, Ivan Ayala, Juan Jose Morales Behaine, Juan Pablo Garcia-Mendez, Hannah Friesen, Kathleen Leistikow, Anirban Bhattacharyya, Arun Jayaraman, Pablo Moreno Franco, et al.

    Background: Delirium, an acute brain dysfunction, is a complication in up to 50% of patients in the intensive care unit (ICU). Measuring and mitigating delirium severity can reduce associated morbidity and improve long-term health outcomes post discharge. However, the perceived complexity of the available delirium detection tools and clinical workload limits the routine assessment of delirium severity. Developing a passive digital marker for delirium severity, combining routine electronic health record (EHR) and computer vision technology data, could be an implementable, scalable, and sustainable approach. Objective: Our primary objective is to develop a passive digital marker for delirium severity (PDM-Del) and examine its performance in comparison to validated delirium severity tools. Our secondary objective is to evaluate the acceptability and usability of the PDM-Del by patients, families, and clinicians. Methods: We will conduct a prospective, longitudinal cohort study to develop a PDM-Del using computer vision data and routinely collected EHR data. Following informed consent, the study team will collect image data through continuous digital video recordings of adult patients (>50 years) in their ICU room, routine EHR data (demographic and clinical variables), and administer delirium severity assessments (4 times daily) until ICU discharge or death. We will examine the usability and acceptability of the developed PDM-Del by patients, families, and direct care clinicians in a pilot randomized controlled clinical trial (aim 3). Descriptive statistics (means, SDs, medians, IQRs, and frequencies) and statistical differences between study instruments will be examined. We will use convolutional neural networks and machine learning to inform model development, testing, and validation. We will report model performance statistics, including accuracy, precision, recall, and the F1-score. Results: We are currently in the recruitment and data collection phase. As of March 2025, we screened 3980 patients (32% eligible, n=1307), approached 665 (50%), and enrolled 150 participants (23% enrollment rate). Among the 150 patients, the median age was 67 (IQR 61-74) years, 62% (93/150) were male, and 91% (136/150) were White. Conclusions: The PDM-Del could provide real-time, actionable feedback to direct care clinicians on the brain health of patients in the ICU. Early mitigation of delirium severity may decrease the risk of mortality, future Alzheimer disease and related dementia, and length of hospital stay. Trial Registration: ClinicalTrials.gov NCT06172491; https://clinicaltrials.gov/study/NCT06172491 International Registered Report Identifier (IRRID): DERR1-10.2196/62912


  • Open Access

    Outcomes with venoarterial vs venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation in interstitial lung disease

    by Prasanth Balasubramanian, Pablo Moreno Franco, Sanjay Chaudhary, Francisco G. Alvarez, Maher Baz, Tathagat Narula, Sadia Z. Shah, Mohammad Alomari, Rohan Bongu, Anirban Bhattacharrya, et al.


  • Open Access

    Elucidating the causal relationship of mechanical power and lung injury: a dynamic approach to ventilator management

    by ChaoPing Wu, Arif Canakoglu, Jacob Vine, Anya Mathur, Ronit Nath, Markos Kashiouris, Piyush Mathur, Ari Ercole, Paul Elbers, Abhijit Duggal, et al.

    Background: Mechanical power (MP) serves as a crucial predictive indicator for ventilator-induced lung injury and plays a pivotal role in tailoring the management of mechanical ventilation. However, its application across different diseases and stages remains nuanced. Methods: Using AmsterdamUMCdb, we conducted a retrospective study to analyze the causal relationship between MP and outcomes of invasive mechanical ventilation, specifically SpO2/FiO2 ratio (P/F) and ventilator-free days at day 28 (VFD28). We employed causal inferential analysis with backdoor linear regression and double machine learning, guided by directed acyclic graphs, to estimate the average treatment effect (ATE) in the whole population and conditional average treatment effect (CATE) in the individual cohort. Additionally, to enhance interpretability and identify MP thresholds, we conducted a simulation analysis. Results: In the study, we included 11,110 unique admissions into analysis, of which 58.3% (6391) were surgical admissions. We revealed a negative and significant causal effect of median MP on VFD28, with estimated ATEs of −0.135 (95% confidence interval [CI]: −0.15 to −0.121). The similar effect was not observed in Maximal MP and minimal MP. The effect of MP was more pronounced in the medical subgroup, with a CATE of −0.173 (95% CI: −0.197 to −0.143) determined through backdoor linear regression. Patients with cardio, respiratory, and infection diagnoses, who required long-term intubation, sustained higher impact on CATEs across various admission diagnoses. Our simulations showed that there is no single MP threshold that can be applied to all patients, as the optimal threshold varies depending on the patient’s condition. Conclusion: Our study underscores the importance of tailoring MP adjustments on an individualized basis in ventilator management. This approach opens up new avenues for personalized treatment strategies and provides fresh insights into the real-time impact of MP in diverse clinical scenarios. It highlights the significance of median MP while acknowledging the absence of universally applicable thresholds.


  • Open Access

    Harnessing the Power of Technology to Transform Delirium Severity Measurement in the Intensive Care Unit: Protocol for a Prospective Cohort Study (Preprint)

    by Roshini Raghu, Keivan Nalaie, Ivan Ayala, Juan Jose Morales Behaine, Juan Pablo Garcia-Mendez, Hannah Friesen, Kathleen Leistikow, Anirban Bhattacharyya, Arun Jayaraman, Pablo Moreno Franco, et al.

    BACKGROUND Delirium, an acute brain dysfunction, is a complication in up to 50% of patients in the intensive care unit (ICU). Measuring and mitigating delirium severity can reduce associated morbidity and improve long-term health outcomes post discharge. However, the perceived complexity of the available delirium detection tools and clinical workload limits the routine assessment of delirium severity. Developing a passive digital marker for delirium severity, combining routine electronic health record (EHR) and computer vision technology data, could be an implementable, scalable, and sustainable approach. OBJECTIVE Our primary objective is to develop a passive digital marker for delirium severity (PDM-Del) and examine its performance in comparison to validated delirium severity tools. Our secondary objective is to evaluate the acceptability and usability of the PDM-Del by patients, families, and clinicians. METHODS We will conduct a prospective, longitudinal cohort study to develop a PDM-Del using computer vision data and routinely collected EHR data. Following informed consent, the study team will collect image data through continuous digital video recordings of adult patients (>50 years) in their ICU room, routine EHR data (demographic and clinical variables), and administer delirium severity assessments (4 times daily) until ICU discharge or death. We will examine the usability and acceptability of the developed PDM-Del by patients, families, and direct care clinicians in a pilot randomized controlled clinical trial (aim 3). Descriptive statistics (means, SDs, medians, IQRs, and frequencies) and statistical differences between study instruments will be examined. We will use convolutional neural networks and machine learning to inform model development, testing, and validation. We will report model performance statistics, including accuracy, precision, recall, and the F1-score. RESULTS We are currently in the recruitment and data collection phase. As of March 2025, we screened 3980 patients (32% eligible, n=1307), approached 665 (50%), and enrolled 150 participants (23% enrollment rate). Among the 150 patients, the median age was 67 (IQR 61-74) years, 62% (93/150) were male, and 91% (136/150) were White. CONCLUSIONS The PDM-Del could provide real-time, actionable feedback to direct care clinicians on the brain health of patients in the ICU. Early mitigation of delirium severity may decrease the risk of mortality, future Alzheimer disease and related dementia, and length of hospital stay. CLINICALTRIAL ClinicalTrials.gov NCT06172491; https://clinicaltrials.gov/study/NCT06172491 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/62912

  • Association of estimated plasma volume with new onset acute kidney injury in hospitalized COVID-19 patients

    by Shahin Isha, Prasanth Balasubramanian, Lekhya Raavi, Abby J. Hanson, Anna Jenkins, Parthkumar Satashia, Arvind Balavenkataraman, Iván A. Huespe, Aysun Tekin, Vikas Bansal, et al.